Get the Stockscreener App
23.72
3.42%
-0.84
Castle Biosciences Inc stock is traded at $23.72, with a volume of 207.33K.
It is down -3.42% in the last 24 hours and up +12.52% over the past month.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
See More
Previous Close:
$24.56
Open:
$24.55
24h Volume:
207.33K
Relative Volume:
0.54
Market Cap:
$719.43M
Revenue:
$339.92M
Net Income/Loss:
$-12.83M
P/E Ratio:
-55.23
EPS:
-0.4295
Net Cash Flow:
$4.52M
1W Performance:
-1.62%
1M Performance:
+12.52%
6M Performance:
-39.71%
1Y Performance:
+19.56%
1-Day Range:
$23.36
$24.66
1-Week Range:
$23.34
$24.80
52-Week Range:
$14.59
$44.28
Castle Biosciences Inc Stock (CSTL) Company Profile
Name
Castle Biosciences Inc
Sector
Industry
Phone
866-788-9007
Address
1500 W. PARKWOOD AVE., FRIENDSWOOD, TX
Compare CSTL vs TMO, DHR, IDXX, NTRA, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
23.72 | 719.43M | 339.92M | -12.83M | 4.52M | -0.4295 |
TMO
Thermo Fisher Scientific Inc
|
527.05 | 195.86B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
199.05 | 140.88B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
563.57 | 44.46B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
269.95 | 38.66B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
134.29 | 37.93B | 7.23B | 1.41B | 1.09B | 4.979 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Apr-30-21 | Initiated | Lake Street | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Dec-27-19 | Reiterated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | BTIG Research | Buy |
| Aug-19-19 | Initiated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | Robert W. Baird | Outperform |
| Aug-19-19 | Initiated | SVB Leerink | Outperform |
View All
Castle Biosciences Inc Stock (CSTL) Latest News
Castle Biosciences Inc (CSTL) Stock Down 3.4% -- Now Undervalued? GF Score: 77/100 - GuruFocus
Castle Biosciences (CSTL) to Release Q2 Financial Results on Jul - GuruFocus
Castle Biosciences sets July 30 webcast for Q2 results - Stock Titan
Castle Biosciences updates its melanoma testing strategy as diagnostics demand grows - ad-hoc-news.de
Castle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus - AOL.com
Castle Biosciences (CSTL) COO sells 8,586 shares under 10b5-1 plan - Stock Titan
Form 4 Castle Biosciences Inc For: 6 July By Investing.com - Investing.com Nigeria
Derek Maetzold, pres. & CEO, sells $238,916 of Castle Biosciences stock - Investing.com
Castle Biosciences (CSTL) CEO sells 9,836 shares via 10b5-1 plan - Stock Titan
The Technical Signals Behind (CSTL) That Institutions Follow - Stock Traders Daily
Q1 2026 Castle Biosciences Inc Earnings Call Transcript - GuruFocus
Enterprise value to revenue forward of Castle Biosciences, Inc. – NASDAQ:CSTL - TradingView
Castle Biosciences Inc (CSTL) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Form 144 Castle Biosciences For: 1 July By Investing.com - Investing.com Canada
Maetzold family Rule 144 sales reported for CSTL (CSTL) — multiple small lots - Stock Titan
Castle Biosciences (CSTL) Surges 6% as Bullish Momentum BuildsMerger Arbitrage - dars.gov.et
Castle Biosciences updates its melanoma test data, shares in biotech focus - AD HOC NEWS
Castle Biosciences (CSTL) Stock Sees Split Analyst Revisions As Price Targets Come Down - Yahoo Finance
Castle Biosciences (CSTL) Study Highlights Advancements in Melan - GuruFocus
Castle Biosciences, Inc. Actuals & Estimates (NASDAQ:CSTL) - TradingView
Castle Biosciences’ melanoma test outperforms risk tool By Investing.com - Investing.com South Africa
Castle Biosciences, Inc. Actuals & Estimates (TRADEGATE:086) - TradingView
Castle Biosciences’ melanoma test outperforms risk tool - Investing.com
Enterprise value to EBIT forward of Castle Biosciences, Inc. – NASDAQ:CSTL - TradingView
DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy - norfolkneradio.com
Roth Capital Initiates Castle Biosciences at Buy - Moomoo
Precision Trading with Castle Biosciences Inc. (CSTL) Risk Zones - Stock Traders Daily
CSTL Forecast — Price Target — Prediction for 2027 - TradingView
CSTL Initiated by Roth Capital -- Price Target Announced at $40. - GuruFocus
Price to earnings forward of Castle Biosciences, Inc. – NASDAQ:CSTL - TradingView
Enterprise value to EBITDA forward of Castle Biosciences, Inc. – NASDAQ:CSTL - TradingView
Enterprise value to revenue forward of Castle Biosciences, Inc. – TRADEGATE:086 - TradingView
Castle Biosciences (CSTL) Receives Buy Rating and $40 Target fro - GuruFocus
Enterprise value to EBIT forward of Castle Biosciences, Inc. – TRADEGATE:086 - TradingView
Castle Biosciences prioritizes people across patients, clinicians, and employees - Traders Union
Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal - Sahm
Castle Biosciences Inc (CSTL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Castle Biosciences CFO receives Houston business award By Investing.com - Investing.com South Africa
Castle Biosciences celebrates Frank Stokes win at Houston Business Journal CFO Awards - Traders Union
Castle Biosciences CFO Frank Stokes Named Houston Business Journal CFO Awards Honoree - citybiz
Castle Biosciences' Chief Financial Officer Frank Stokes Named a - GuruFocus
Castle Biosciences CFO receives Houston business award - Investing.com
Castle Biosciences CFO Frank Stokes named among 22 Houston finance leaders - Stock Titan
CSTL Q1 2026 Earnings: Narrowly Exceeds EPS Estimates, Stock Edges HigherRetail Earnings Report - dars.gov.et
Castle Biosciences Inc (CSTL) Institutional Confidence - TradingKey
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Castle Biosciences (CSTL) COO sells 8,587 shares, retains over 127K - Stock Titan
Castle Biosciences Inc (CSTL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Castle Biosciences Inc (CSTL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Castle Biosciences Inc (CSTL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Castle Biosciences Inc (CSTL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Castle Biosciences Inc Stock (CSTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.29%
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):